Medical Center Askela Innovations OOD

Research site

Bulgaria Ulitsa Geo Milev 153b, 1574 Sofia, Bulgaria

3 trials recruiting
Angina pectoris · Arteriosclerosis · Cardiovascular disorder
Adult patients

About Specializations

Medical Center Askela Innovations OOD in Sofia, Bulgaria specialises in clinical trials of conditions such as Angina pectoris, Arteriosclerosis, Cardiovascular disorder, Heart failure with preserved ejection fraction, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiology

The medical center is at the forefront of cardiology research, focusing on innovative treatments for heart-related conditions. The ongoing research aims to enhance the understanding and management of cardiovascular diseases, particularly in the area of stable angina pectoris.

Stable Angina Pectoris
Anti-anginal Therapies
Cardiovascular Health

Through the ORESA Study, the center is dedicated to confirming the efficacy of novel therapeutic agents like T89, which are designed to alleviate symptoms and improve the quality of life for patients with chronic stable angina.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ulitsa Geo Milev 153b1574 SofiaBulgaria

Open in maps ↗

Recruiting now: 3 trials
Conditions studied: 5

More sites in Sofia Bulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

4 clinical trials

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:Laroprovstat
Sponsor:AstraZeneca AB

Contact Research Centre

Heart failure with preserved ejection fraction

Recruiting

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:AZD5004
Sponsor:AstraZeneca AB

Contact Research Centre

Angina pectoris

Not yet recruiting

Study on the Effects of T89 and Glyceryl Trinitrate for Patients with Stable Angina

Registered drug

Study on the Effects of T89 and Glyceryl Trinitrate for Patients with Stable Angina

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Glyceryl Trinitrate
Sponsor:Tasly Pharmaceuticals Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites